The eye disease device developer has raised series B funding to advance research originating from University of Colorado's s Sue Anschutz-Rodgers Eye Center.

Pfizer's Breakthrough Growth Initiative has backed the PureTech microbiome spinoff, which will use the cash to finance phase 2 tests of its lead IBD drug candidate.

The book publisher and nursing care service group’s Gakken Innovation-Tech Fund plans to invest about $29m over the next five years, targeting edtech and healthtech.

Heska has agreed to buy the R/GA-backed veterinary telemedicine platform developer in a deal set to close later this quarter.

GlaxoSmithKline has exited the CDS platform operator, which has been purchased by patient care software provider Amalgam Rx for an undisclosed sum.

Echo Health Ventures has joined Arkansas Blue Cross Blue Shield's investment arm in a strategic initiative aimed at scaling up healthcare businesses.

The Sinopharm and WuXi AppTec-backed, complement system-focused drug developer has hauled in $53.3m of new funding after emerging from stealth late last year.

The cardiovascular treatment device developer raised about $46m in a round led by Tencent and has now secured roughly $60m altogether.

The transistor technology developer has disclosed $21.8m in series A funding from investors including Agilent Technologies across three tranches.

Weill Cornell Medicine‘s monogenic diseases therapy developer Lexeo Therapeutics has made its public debut with $85m in series A financing.